Europe Cardiac Safety Services Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-24
- Report ID: 143370
- Pages: 225
-
Format:
Short Description
Europe Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029
Market Definition:
Cardiac safety services generally help support and design clinical trials and other research needed to monitor heart safety. The demand for cardiac safety services market has been increased in both developed well as in developing countries and the reason behind this is the increasing number of clinical trials and product launch. The cardiac safety services market is growing due to introduction of innovative products, increasing in technological products and rising disposable income. The market will grow in forecasted period due to exploration of emerging markets, strategic initiatives by market players, increasing healthcare expenditure.
Market Segmentation:
The cardiac safety services market is categorized into four notable segment which is services, type, phase and end user.
On the basis of services, the cardiac safety services market is segmented into ECG/Holter measurements, blood pressure measurements, in vitro cardiac safety assessment services, cardiovascular imaging, real-time telemetry monitoring, central over-read of ECGS, non-invasive cardiac imaging, physiologic stress testing, thorough QT studies, TQT and exposure response modeling, platelet aggregation and other services.
On the basis of phases, the cardiac safety services market is segmented into phase 1, phase 2 and phase 3. In 2022, phase 1 is expected to dominate the global cardiac safety services market with the increasing new drug development and rising strategic initiatives by major market players.
On the basis of type, the cardiac safety services market is segmented into integrated services and standalone services. In 2022, integrated services is expected to dominate the global cardiac safety services market with the increasing advanced technology and rising healthcare expenditure.
On the basis of end user, the cardiac safety services market is segmented pharmaceuticals & biopharmaceuticals companies, contract research organizations and academic and research institute. In 2022, hospital is expected to dominate the global cardiac safety services market with the increasing number of patients and surgeries.
Market Players
The key market players for Europe cardiac safety services market are listed below:
Koninklijke Philips N.V.
Laboratory Corporation of America Holdings
IQVIA
Medpace
Ncardia
Certara
Eurofins Scientific
SGS SA
Banook
Celerion
Biotrial
Richmond Pharmacology
PhysioStim
TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF EUROPE CARDIAC SAFETY SERVICES MARKET 26
1.4 LIMITATIONS 27
1.5 MARKETS COVERED 28
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 CURRENCY AND PRICING 32
2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
2.6 MULTIVARIATE MODELLING 36
2.7 SERVICES LIFELINE CURVE 36
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.9 DBMR MARKET POSITION GRID 38
2.10 MARKET END USER GRID 40
2.11 VENDOR SHARE ANALYSIS 41
2.12 SECONDARY SOURCES 42
2.13 ASSUMPTIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 46
4.1 PORTERS FIVE FORCES 47
4.2 PESTEL ANALYSIS 48
5 EPIDEMIOLOGY 49
5.1 INCIDENCE OF ALL BY GENDER 49
5.2 TREATMENT RATE 50
5.3 MORTALITY RATE 50
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 51
6 INDUSTRY INSIGHT 52
6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52
6.2 PATENT ANALYSIS 53
6.3 PATENT FLOW DIAGRAM 54
6.4 KEY PATIENT ENROLLMENT STRATEGIES 54
6.5 PRICING STRATEGY 57
7 EUROPE CARDIAC SAFETY SERVICES MARKET: REGULATIONS 58
8 MARKET OVERVIEW 61
8.1 DRIVERS 63
8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 63
8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 63
8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64
8.1.4 INCREASE IN R&D ACTIVITIES 64
8.2 RESTRAINTS 65
8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 65
8.2.2 STRICT REGULATORY 65
8.3 OPPORTUNITIES: 66
8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 66
8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 67
8.4 CHALLENGES 67
8.4.1 TIME-CONSUMING PROCEDURE 67
8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 68
9 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES 69
9.1 OVERVIEW 70
9.2 ECG/HOLTER MEASUREMENTS 74
9.3 BLOOD PRESSURE MEASUREMENTS 74
9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 75
9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 76
9.4.1.1 1 CONCENTRATIONS 76
9.4.1.2 4 CONCENTRATIONS 76
9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 77
9.4.2.1 3 CONCENTRATIONS 77
9.4.2.2 5 CONCENTRATIONS 77
9.4.3 IN VITRO HERG ASSAY 77
9.4.4 OTHERS 77
9.5 CARDIOVASCULAR IMAGING 77
9.6 REAL TIME TELEMETRY MONITORING 78
9.7 CENTRAL OVER-READ OF ECGS 79
9.8 NON-INVASIVE CARDIAC IMAGING 79
9.9 PHYSIOLOGIC STRESS TESTING 80
9.10 THOROUGH QT STUDIES 81
9.11 TQT AND EXPOSURE RESPONSE MODELLING 81
9.12 PLATELET AGGREGATION 82
9.13 OTHERS 83
10 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE 84
10.1 OVERVIEW 85
10.2 PHASE I 88
10.3 PHASE II 88
10.4 PHASE III 89
11 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE 90
11.1 OVERVIEW 91
11.2 INTEGRATED SERVICES 94
11.3 STANDALONE SERVICES 95
12 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER 96
12.1 OVERVIEW 97
12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 100
12.3 CONTRACT RESEARCH ORGANIZATIONS 100
12.4 ACADEMIC AND RESEARCH INSTITUTE 101
13 EUROPE CARDIAC SAFETY SERVICES MARKET, BY REGION 102
13.1 EUROPE 103
13.1.1 GERMANY 111
13.1.2 FRANCE 114
13.1.3 U.K. 117
13.1.4 ITALY 120
13.1.5 SPAIN 123
13.1.6 TURKEY 126
13.1.7 RUSSIA 129
13.1.8 NETHERLANDS 132
13.1.9 SWITZERLAND 135
13.1.10 BELGIUM 138
13.1.11 REST OF EUROPE 141
14 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 142
14.1 COMPANY SHARE ANALYSIS: EUROPE 142
15 COMPANY PROFILE 143
15.1 EUROFINS SCIENTIFIC 143
15.1.1 COMPANY SNAPSHOT 143
15.1.2 REVENUE ANALYSIS 144
15.1.3 COMPANY SHARE ANALYSIS 144
15.1.4 PRODUCT PORTFOLIO 144
15.1.5 RECENT DEVELOPMENTS 145
15.1.5.1 AGREEMENTS 145
15.1.5.2 ACQUISITION 145
15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 146
15.2.1 COMPANY SNAPSHOT 146
15.2.2 REVENUE ANALYSIS 146
15.2.3 COMPANY SHARE ANALYSIS 147
15.2.4 PRODUCT PORTFOLIO 147
15.2.5 RECENT DEVELOPMENT 147
15.2.5.1 INVESTMENT 147
15.3 KONINKLIJKE PHILIPS N.V. 148
15.3.1 COMPANY SNAPSHOT 148
15.3.2 REVENUE ANALYSIS 148
15.3.3 COMPANY SHARE ANALYSIS 149
15.3.4 PRODUCT PORTFOLIO 149
15.3.5 RECENT DEVELOPMENT 149
15.3.5.1 ACQUISITION 149
15.4 IQVIA 150
15.4.1 COMPANY SNAPSHOT 150
15.4.2 REVENUE ANALYSIS 150
15.4.3 COMPANY SHARE ANALYSIS 151
15.4.4 PRODUCT PORTFOLIO 151
15.4.5 RECENT DEVELOPMENTS 151
15.4.5.1 ACQUISITION 151
15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 152
15.5.1 COMPANY SNAPSHOT 152
15.5.2 REVENUE ANALYSIS 152
15.5.3 COMPANY SHARE ANALYSIS 153
15.5.4 PRODUCT PORTFOLIO 153
15.5.5 RECENT DEVELOPMENTS 153
15.5.5.1 NEW LABORATORY 153
15.5.5.2 ACQUISITION 153
15.6 BANOOK 154
15.6.1 COMPANY SNAPSHOT 154
15.6.2 PRODUCT PORTFOLIO 154
15.6.3 RECENT DEVELOPMENT 154
15.6.3.1 AGREEMENT 154
15.7 BIOTRIAL 155
15.7.1 COMPANY SNAPSHOT 155
15.7.2 PRODUCT PORTFOLIO 155
15.7.3 RECENT DEVELOPMENT 155
15.7.3.1 NEW CENTER OPENING 155
15.8 CELERION 156
15.8.1 COMPANY SNAPSHOT 156
15.8.2 PRODUCT PORTFOLIO 156
15.8.3 RECENT DEVELOPMENT 156
15.8.3.1 NEW CENTER OPENING 156
15.9 CERTARA 157
15.9.1 COMPANY SNAPSHOT 157
15.9.2 REVENUE ANALYSIS 157
15.9.3 PRODUCT PORTFOLIO 158
15.9.4 RECENT DEVELOPMENTS 158
15.9.4.1 CONTRACT 158
15.9.4.2 ACQUISITION 158
15.10 CLARIO 159
15.10.1 COMPANY SNAPSHOT 159
15.10.2 PRODUCT PORTFOLIO 159
15.10.3 RECENT DEVELOPMENT 159
15.10.3.1 PRODUCT EXPANSION 159
15.11 MEDPACE 160
15.11.1 COMPANY SNAPSHOT 160
15.11.2 REVENUE ANALYSIS 160
15.11.3 PRODUCT PORTFOLIO 161
15.11.4 RECENT DEVELOPMENTS 161
15.11.4.1 ACQUISITION 161
15.12 NCARDIA 162
15.12.1 COMPANY SNAPSHOT 162
15.12.2 PRODUCT PORTFOLIO 162
15.12.3 RECENT DEVELOPMENT 162
15.12.3.1 PARTNERSHIP 162
15.13 NEXEL CO., LTD 163
15.13.1 COMPANY SNAPSHOT 163
15.13.2 PRODUCT PORTFOLIO 163
15.13.3 RECENT DEVELOPMENTS 163
15.13.3.1 JOINT VENTURE 163
15.13.3.2 PARTNERSHIP 164
15.14 PHYSIOSTIM 165
15.14.1 COMPANY SNAPSHOT 165
15.14.2 PRODUCT PORTFOLIO 165
15.14.3 RECENT DEVELOPMENT 165
15.14.3.1 PARTNERSHIP 165
15.15 RICHMOND PHARMACOLOGY 166
15.15.1 COMPANY SNAPSHOT 166
15.15.2 PRODUCT PORTFOLIO 166
15.15.3 RECENT DEVELOPMENT 166
15.15.3.1 EVENT 166
15.16 SGS SA 167
15.16.1 COMPANY SNAPSHOT 167
15.16.2 REVENUE ANALYSIS 167
15.16.3 PRODUCT PORTFOLIO 168
15.16.4 RECENT DEVELOPMENT 168
15.16.4.1 ACQUISITION 168
15.17 SHANGHAI MEDICILON INC. 169
15.17.1 COMPANY SNAPSHOT 169
15.17.2 PRODUCT PORTFOLIO 169
15.17.3 RECENT DEVELOPMENTS 169
15.17.3.1 PARTNERSHIP 169
15.17.3.2 PARTNERSHIP 170
16 QUESTIONNAIRE 171
17 RELATED REPORTS 173
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
